TY - JOUR AU - Gueler, A. AU - Moser, A. AU - Calmy, A. AU - Gunthard, H. F. AU - Bernasconi, E. AU - Furrer, H. PY - 2017 DA - 2017// TI - Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population JO - AIDS. VL - 31 ID - Gueler2017 ER - TY - JOUR AU - Wandeler, G. AU - Johnson, L. F. AU - Egger, M. PY - 2016 DA - 2016// TI - Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population JO - Curr Opin HIV AIDS VL - 11 UR - https://doi.org/10.1097/COH.0000000000000298 DO - 10.1097/COH.0000000000000298 ID - Wandeler2016 ER - TY - JOUR AU - Smit, M. AU - Brinkman, K. AU - Geerlings, S. AU - Smit, C. AU - Thyagarajan, K. AU - Sighem, A. PY - 2015 DA - 2015// TI - Future challenges for clinical care of an ageing population infected with HIV: a modelling study JO - Lancet Infect Dis VL - 15 UR - https://doi.org/10.1016/S1473-3099(15)00056-0 DO - 10.1016/S1473-3099(15)00056-0 ID - Smit2015 ER - TY - BOOK PY - 2016 DA - 2016// TI - Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection ID - ref4 ER - TY - JOUR AU - Fux, C. A. AU - Simcock, M. AU - Wolbers, M. AU - Bucher, H. C. AU - Hirschel, B. AU - Opravil, M. PY - 2007 DA - 2007// TI - Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV cohort study JO - Antivir Ther VL - 12 ID - Fux2007 ER - TY - JOUR AU - Hall, A. M. AU - Hendry, B. M. AU - Nitsch, D. AU - Connolly, J. O. PY - 2011 DA - 2011// TI - Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence JO - Am J Kidney Dis VL - 57 UR - https://doi.org/10.1053/j.ajkd.2011.01.022 DO - 10.1053/j.ajkd.2011.01.022 ID - Hall2011 ER - TY - JOUR AU - Bedimo, R. AU - Maalouf, N. M. AU - Zhang, S. AU - Drechsler, H. AU - Tebas, P. PY - 2012 DA - 2012// TI - Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents JO - AIDS. VL - 26 UR - https://doi.org/10.1097/QAD.0b013e32835192ae DO - 10.1097/QAD.0b013e32835192ae ID - Bedimo2012 ER - TY - JOUR AU - McComsey, G. A. AU - Kitch, D. AU - Daar, E. S. AU - Tierney, C. AU - Jahed, N. C. AU - Tebas, P. PY - 2011 DA - 2011// TI - Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids clinical trials group A5224s, a substudy of ACTG A5202 JO - J Infect Dis VL - 203 UR - https://doi.org/10.1093/infdis/jir188 DO - 10.1093/infdis/jir188 ID - McComsey2011 ER - TY - JOUR AU - Mills, A. AU - Arribas, J. R. AU - Andrade-Villanueva, J. AU - DiPerri, G. AU - Lunzen, J. AU - Koenig, E. PY - 2016 DA - 2016// TI - Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study JO - Lancet Infect Dis VL - 16 UR - https://doi.org/10.1016/S1473-3099(15)00348-5 DO - 10.1016/S1473-3099(15)00348-5 ID - Mills2016 ER - TY - JOUR AU - Post, F. A. AU - Tebas, P. AU - Clarke, A. AU - Cotte, L. AU - Short, W. R. AU - Abram, M. E. PY - 2017 DA - 2017// TI - Brief report: switching to Tenofovir Alafenamide, Coformulated with Elvitegravir, Cobicistat, and Emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study JO - J Acquir Immune Defic Syndr VL - 74 UR - https://doi.org/10.1097/QAI.0000000000001186 DO - 10.1097/QAI.0000000000001186 ID - Post2017 ER - TY - JOUR AU - Saag, M. S. AU - Benson, C. A. AU - Gandhi, R. T. AU - Hoy, J. F. AU - Landovitz, R. J. AU - Mugavero, M. J. PY - 2018 DA - 2018// TI - Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel JO - JAMA. VL - 320 UR - https://doi.org/10.1001/jama.2018.8431 DO - 10.1001/jama.2018.8431 ID - Saag2018 ER - TY - STD TI - European AIDS Clinical Society (EACS). Guidelines for the treatment of HIV-positive adults. October 2018. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed 13 Aug 2019. UR - http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html ID - ref12 ER - TY - JOUR AU - Schoeni-Affolter, F. AU - Ledergerber, B. AU - Rickenbach, M. AU - Rudin, C. AU - Gunthard, H. F. AU - Telenti, A. PY - 2010 DA - 2010// TI - Cohort profile: the Swiss HIV cohort study JO - Int J Epidemiol VL - 39 UR - https://doi.org/10.1093/ije/dyp321 DO - 10.1093/ije/dyp321 ID - Schoeni-Affolter2010 ER - TY - STD TI - Liverpool Drug Interaction Group UoL. Prescribing resources: interactions with NRTI 2018 [Available from: https://www.hiv-druginteractions.org/. Accessed 13 Aug 2019. UR - https://www.hiv-druginteractions.org/ ID - ref14 ER - TY - STD TI - Bickel M, Wyen C, Spinner C, Baumgarten A. Switch from tenofovir disoproxil fumarate (TDF)- to tenofovir alafenamide (TAF)-based regimens in clinical practice - real-world data of the German PROPHET cohort study: HIV Glasgow; 2018. ID - ref15 ER - TY - STD TI - Elion R, Eron J, Santiago S, Sax P. Clinical observations of antiretroviral (ART) switching in HIV-suppressed patients after availability of TAF: HIV Glasgow; 2018. ID - ref16 ER - TY - STD TI - Brown K, Sutherland G, O'Hara R, Bell D, editors. Real world experience using Tenofovir Alafenamide fumarate. UK. HIV Glasgow; 2018. ID - ref17 ER - TY - STD TI - Vergori A, Lorenzini P, Cozzi-Lepri A, Maggiolo F. Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation cohort: HIV Glasgow; 2018. ID - ref18 ER - TY - JOUR AU - Pozniak, A. AU - Arribas, J. R. AU - Gathe, J. AU - Gupta, S. K. AU - Post, F. A. AU - Bloch, M. PY - 2016 DA - 2016// TI - Switching to Tenofovir Alafenamide, Coformulated with Elvitegravir, Cobicistat, and Emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study JO - J Acquir Immune Defic Syndr VL - 71 UR - https://doi.org/10.1097/QAI.0000000000000908 DO - 10.1097/QAI.0000000000000908 ID - Pozniak2016 ER - TY - JOUR AU - Goicoechea, M. AU - Liu, S. AU - Best, B. AU - Sun, S. AU - Jain, S. AU - Kemper, C. PY - 2008 DA - 2008// TI - Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy JO - J Infect Dis VL - 197 UR - https://doi.org/10.1086/524061 DO - 10.1086/524061 ID - Goicoechea2008 ER - TY - JOUR AU - Hill, A. AU - Hughes, S. L. AU - Gotham, D. AU - Pozniak, A. L. PY - 2018 DA - 2018// TI - Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? JO - J Virus Erad VL - 4 ID - Hill2018 ER - TY - STD TI - Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019:dkz068. ID - ref22 ER -